to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Cohen, Russell D.
One or more keywords matched the following items that are connected to
Cohen, Russell D.
Tumor Necrosis Factor-alpha
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.
Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.
Infliximab in ulcerative colitis: is there a placebo (effect) in the house?
The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies.
Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT? Registry.
Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis.
Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.
Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report.
The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
The Effect of Maternal Peripartum Anti-TNFa Use on Infant Immune Response.
Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases.
Maneuvering Clinical Pathways for Crohn's Disease.
Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease.
Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn's disease.
Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch-Anal Anastomosis in Pediatric Ulcerative Colitis.
Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery.
Tumor Necrosis Factor alpha